Followers | 813 |
Posts | 71326 |
Boards Moderated | 2 |
Alias Born | 01/30/2003 |
Wednesday, September 07, 2016 2:09:24 PM
The goals of this 28-day study were to assess the effect of different dosing regimens of BCX4430 administered by i.m. injection on survival in rhesus macaques with established Ebola virus disease. The study consisted of three treatment groups of six animals each treated with different BCX4430 dosing schedules and one control group of six animals.
Following inoculation of virus on Day 0, 6 of 6 (100%) animals survived after receiving 100 mg/kg BCX4430 twice on day 2, followed by 25 mg/kg twice daily for an additional nine days, compared to none of 6 controls (p < 0.001). Animals treated with the same loading and maintenance dose regimen of BCX4430, but starting on day 3, also showed improved survival (4 of 6, 67%, p = 0.005), as did animals treated with 25 mg/kg of BCX4430 twice daily for 14 days starting on day 2 (4 of 6, 67%, p = 0.005).
Recent BCRX News
- BioCryst to Report First Quarter 2024 Financial Results on May 6 • GlobeNewswire Inc. • 04/22/2024 11:00:50 AM
- BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency • GlobeNewswire Inc. • 04/17/2024 08:30:39 AM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/03/2024 11:00:23 AM
- BioCryst to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 03/25/2024 08:01:00 PM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/05/2024 12:01:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:25:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:32:01 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 02/27/2024 10:05:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:05:56 PM
- BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones • GlobeNewswire Inc. • 02/26/2024 12:00:05 PM
- U.S. Index Futures Dip Amid Inflation Data Anticipation, Oil and Iron Ore Prices Retreat • IH Market News • 02/26/2024 10:57:28 AM
- BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment • GlobeNewswire Inc. • 02/23/2024 12:00:00 PM
- BioCryst to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/21/2024 09:01:58 PM
- BioCryst Launches ORLADEYO® (berotralstat) in Italy • GlobeNewswire Inc. • 02/19/2024 12:54:52 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:21:51 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 02:02:50 PM
- BioCryst to Report Fourth Quarter 2023 Financial Results on February 26 • GlobeNewswire Inc. • 02/12/2024 12:00:53 PM
- BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting • GlobeNewswire Inc. • 02/05/2024 12:00:00 PM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/02/2024 12:00:48 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/24/2024 10:23:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 10:21:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:02:39 PM
- BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability • GlobeNewswire Inc. • 01/05/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:31:49 PM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/03/2024 09:01:59 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM